Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

British Journal of Dermatology

Volumn 176, Issue 1, 2017, Pages 231-233

  Ang, C C ^a,b,c   Anyanwu, C O ^a,b   Robinson, E ^a,b   Okawa, J ^a,b   Feng, R ^d   Fujimoto, M ^e   Hamaguchi, Y ^f   Werth, V P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHANGI GENERAL HOSPITAL   (Singapore)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

JO 1 ANTIBODY; BIOLOGICAL MARKER;

BLOOD SAMPLING; DERMATOMYOSITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG BIOPSY; PAPULE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; ADULT; AGED; COMPLICATION; FEMALE; HAND DISEASE; LUNG DISEASES, INTERSTITIAL; MALE; METABOLISM; MIDDLE AGED; ONSET AGE; YOUNG ADULT;

ADULT; AGE OF ONSET; AGED; BIOMARKERS; DERMATOMYOSITIS; FEMALE; HAND DERMATOSES; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 85001842999     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14801     Document Type: Letter

References (11)

1. Morganroth PA, Kreider ME, Okawa J et al. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol 2010; 146:729–38.
2. Fathi M, Lundberg IE, Tornling G. Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med 2007; 28:451–8.
3. Marie I, Hatron PY, Dominique S et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63:3439–47.
4. Hamaguchi Y, Fujimoto M, Matsushita T et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 2013; 8:e60442.
5. Marie I, Lahaxe L, Benveniste O et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010; 162:337–44.
6. Fiorentino D, Chung L, Zwerner J et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25–34.
7. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344–7.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403–7.
9. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24:959–66.
10. Gerami P, Schope JM, McDonald L et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597–613.
11. Hamaguchi Y, Kuwana M, Hoshino K et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147:391–8.